Literature DB >> 19454660

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.

Joseph F Grosso1, Monica V Goldberg, Derese Getnet, Tullia C Bruno, Hung-Rong Yen, Kristin J Pyle, Edward Hipkiss, Dario A A Vignali, Drew M Pardoll, Charles G Drake.   

Abstract

Lymphocyte Activation Gene-3 (LAG-3) is a transmembrane protein that binds MHC class II, enhances regulatory T cell activity, and negatively regulates cellular proliferation, activation, and homeostasis of T cells. Programmed Death 1 (PD-1) also negatively regulates T cell function. LAG-3 and PD-1 are both transiently expressed on CD8 T cells that have been stimulated during acute activation. However, both LAG-3 and PD-1 remain on CD8 T cells at high levels after stimulation within tolerizing environments. Our previous data demonstrated that blockade of either LAG-3 or PD-1 using mAb therapy in combination with vaccination restores the function of tolerized Ag-specific CD8 T cells in models of self and tumor tolerance. It is unclear whether tolerized CD8 T cells coexpress PD-1 and LAG-3 or whether PD-1 and LAG-3 mark functionally distinct populations of CD8 T cells. In this study, we describe three populations of CD8 T cells activated under tolerizing conditions based on LAG-3 and PD-1 staining, each with distinct phenotypic and functional characteristics. From a mechanistic perspective, both Ag concentration and proinflammatory signals control the expression of LAG-3 and PD-1 phenotypes on CD8 T cells under activating and tolerizing conditions. These results imply that signaling through the PD-1 and LAG-3 pathways have distinct functional consequences to CD8 T cells under tolerizing conditions and manipulation of both Ag and cytokine signaling can influence CD8 tolerance through LAG-3 and PD-1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454660      PMCID: PMC3082361          DOI: 10.4049/jimmunol.0804211

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

Review 1.  TLR signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

Review 2.  Cooperation of Toll-like receptor signals in innate immune defence.

Authors:  Giorgio Trinchieri; Alan Sher
Journal:  Nat Rev Immunol       Date:  2007-03       Impact factor: 53.106

3.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Authors:  Monica V Goldberg; Charles H Maris; Edward L Hipkiss; Andrew S Flies; Lijie Zhen; Rubin M Tuder; Joseph F Grosso; Timothy J Harris; Derese Getnet; Katharine A Whartenby; Dirk G Brockstedt; Thomas W Dubensky; Lieping Chen; Drew M Pardoll; Charles G Drake
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

4.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

Review 5.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

6.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

Authors:  E John Wherry; Sang-Jun Ha; Susan M Kaech; W Nicholas Haining; Surojit Sarkar; Vandana Kalia; Shruti Subramaniam; Joseph N Blattman; Daniel L Barber; Rafi Ahmed
Journal:  Immunity       Date:  2007-10-18       Impact factor: 31.745

Review 7.  CD8 T cell dysfunction during chronic viral infection.

Authors:  Haina Shin; E John Wherry
Journal:  Curr Opin Immunol       Date:  2007-07-25       Impact factor: 7.486

8.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Authors:  Joseph F Grosso; Cristin C Kelleher; Timothy J Harris; Charles H Maris; Edward L Hipkiss; Angelo De Marzo; Robert Anders; George Netto; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 9.  Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade.

Authors:  Gordon J Freeman; E John Wherry; Rafi Ahmed; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-09-25       Impact factor: 14.307

10.  Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells.

Authors:  Hirokazu Hikono; Jacob E Kohlmeier; Shiki Takamura; Susan T Wittmer; Alan D Roberts; David L Woodland
Journal:  J Exp Med       Date:  2007-07-02       Impact factor: 14.307

View more
  107 in total

1.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

Review 2.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

3.  Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Authors:  Jens Schreiner; Daniela S Thommen; Petra Herzig; Marina Bacac; Christian Klein; Andreas Roller; Anton Belousov; Victor Levitsky; Spasenija Savic; Wolfgang Moersig; Franziska Uhlenbrock; Viola A Heinzelmann-Schwarz; Pablo Umana; Pavel Pisa; M von Bergwelt-Baildon; Didier Lardinois; Philipp Müller; Vaios Karanikas; Alfred Zippelius
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

4.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

Review 5.  Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.

Authors:  Rajarsi Mandal; Timothy A Chan
Journal:  Cancer Discov       Date:  2016-04-22       Impact factor: 39.397

6.  Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.

Authors:  Alex B Blair; Lei Zheng
Journal:  Chin Clin Oncol       Date:  2017-06

Review 7.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

8.  Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

Authors:  Anne Fröhlich; Judith Sirokay; Simon Fietz; Timo J Vogt; Jörn Dietrich; Romina Zarbl; Mike Florin; Pia Kuster; Gonzalo Saavedra; Susana Ramírez Valladolid; Friederike Hoffmann; Lukas Flatz; Sandra S Ring; Carsten Golletz; Torsten Pietsch; Sebastian Strieth; Peter Brossart; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

9.  Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma.

Authors:  Laura Pinton; Samantha Solito; Elena Masetto; Marina Vettore; Stefania Canè; Alessandro Della Puppa; Susanna Mandruzzato
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

Review 10.  Melanoma immunotherapy.

Authors:  Martina Sanlorenzo; Igor Vujic; Christian Posch; Akshay Dajee; Adam Yen; Sarasa Kim; Michelle Ashworth; Michael D Rosenblum; Alain Algazi; Simona Osella-Abate; Pietro Quaglino; Adil Daud; Susanna Ortiz-Urda
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.